Drugs, Pregnancy & Lactation

Q&A with the FDA: Implementing the Pregnancy and Lactation Labeling Rule


 

Q: Does the FDA have any plans to address labeling for over-the-counter products in terms of their impact on pregnancy, lactation, and reproductive potential?

A: The PLLR does not apply to over-the-counter products. However, the agency is continually reviewing the safety of products used over the counter, including impacts on pregnancy, lactation, and reproductive potential.

Q: How does the FDA plan to assess over time the usefulness of the new labeling for prescribers and patients and make revisions?

A: The draft guidance was issued concurrently with PLLR. Based on the comments received from the public on the draft, as well as learning from the initial revisions of labeling, the guidance will be revised as needed. Guidance statements issued by FDA are regularly reviewed and revised as needed.

Dr. Whyte, a board-certified internist, is the director of Professional Affairs and Stakeholder Engagement at the FDA. Do you have other questions about the PLLR? Send them to obnews@frontlinemedcom.com.

Pages

Recommended Reading

Pregnancy exposure registries confirmed useful in assessing product safety
MDedge Rheumatology
VIDEO: Experts offer top tips for flu season 2014-2015
MDedge Rheumatology
Children born to mothers with RA more likely to be born early
MDedge Rheumatology
FDA issues new pregnancy/lactation drug label standards
MDedge Rheumatology
Consider biopsy for active lupus nephritis in pregnancy
MDedge Rheumatology
Evaluating the impact of FDA’s pregnancy and lactation labeling rule
MDedge Rheumatology
Preeclampsia in SLE ups CVD risk
MDedge Rheumatology
CDC: Opioid use high among reproductive age women
MDedge Rheumatology
High interferon levels related to preeclampsia in pregnant lupus patients
MDedge Rheumatology
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge Rheumatology

Related Articles